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Background. Cough is the major determinant of tuberculosis transmission. Despite this, there is a paucity of information 
regarding characteristics of cough frequency throughout the day and in response to tuberculosis therapy. Here we evaluate the circa-
dian cycle of cough, cough frequency risk factors, and the impact of appropriate treatment on cough and bacillary load.
Methods. We prospectively evaluated human immunodeficiency virus–negative adults (n = 64) with a new diagnosis of cul-
ture-proven, drug-susceptible pulmonary tuberculosis immediately prior to treatment and repeatedly until treatment day 62. At each 
time point, participant cough was recorded (n = 670) and analyzed using the Cayetano Cough Monitor. Consecutive coughs at least 
2 seconds apart were counted as separate cough episodes. Sputum samples (n = 426) were tested with microscopic-observation drug 
susceptibility broth culture, and in culture-positive samples (n = 252), the time to culture positivity was used to estimate bacillary 
load.
Results. The highest cough frequency occurred from 1 pm to 2 pm, and the lowest from 1 am to 2 am (2.4 vs 1.1 cough episodes/
hour, respectively). Cough frequency was higher among participants who had higher sputum bacillary load (P < .01). Pretreatment 
median cough episodes/hour was 2.3 (interquartile range [IQR], 1.2–4.1), which at 14 treatment days decreased to 0.48 (IQR, 0.0–
1.4) and at the end of the study decreased to 0.18 (IQR, 0.0–0.59) (both reductions P < .001). By 14 treatment days, the probability 
of culture conversion was 29% (95% confidence interval, 19%–41%).
Conclusions. Coughs were most frequent during daytime. Two weeks of appropriate treatment significantly reduced cough fre-
quency and resulted in one-third of participants achieving culture conversion. Thus, treatment by 2 weeks considerably diminishes, 
but does not eliminate, the potential for airborne tuberculosis transmission.
Keywords. tuberculosis; airborne transmission; infectiousness; cough; Peru.
 
In 2015, there were an estimated 10.4 million new tuberculo-
sis cases causing 1.4 million deaths worldwide [1]. The major 
means by which transmission occurs is believed to be through 
aerosolized Mycobacterium tuberculosis expelled from an infec-
tious person. A series of classic experiments in the 1960s showed 
that the number of M.  tuberculosis droplet nuclei formed by 
coughing greatly exceeded those formed by singing or speak-
ing, and concluded that cough is the main pathway by which 
bacilli are transmitted from the lung into the environment [2].
Cough frequency has been suggested as a predictor of trans-
mission risk, and high cough frequency late in treatment has 
been associated with treatment failure [3, 4]. However, a recent 
review highlighted the paucity of information related to the 
dynamics of cough in tuberculosis [3]. This review noted that 
the last study reporting the frequency of cough among patients 
undergoing tuberculosis treatment was conducted nearly 
50 years ago and only included an 8-hour overnight assessment 
of 20 patients [5]. Though it is logistically convenient to monitor 
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solely nocturnal cough patterns, it is not known whether day-
time coughs show similar patterns.
In this prospective cohort study, we recorded cough fre-
quency using an objective acoustic tool [6, 7], as is the current 
recommendation [8]. We surveyed participants before and dur-
ing tuberculosis treatment to investigate (1) the circadian cycle, 
(2) risk factors associated with cough, and (3) the impact of 
appropriate treatment on cough frequency and mycobacterial 
burden.
METHODS
Study Design
The parent prospective cohort study followed adults (aged 
≥18  years) with a clinically suspected diagnosis of pulmonary 
tuberculosis in 2 reference tertiary academic Peruvian Hospitals: 
Hospital Nacional Dos de Mayo and Hospital Nacional Daniel 
Alcides Carrión, for which a protocol detailing sample size, 
selection criteria, and detailed information on variables has been 
published [9]. Data for human immunodeficiency virus (HIV)–
infected participants and those who did not have confirmed 
drug-susceptible pulmonary tuberculosis are being reported 
separately. For the current study, inclusion criteria were the sub-
set of the parent study with sputum culture–positive tuberculo-
sis confirmed to be susceptible to isoniazid and rifampicin (to 
reduce the risk of incorrect treatment confounding results) in 
participants confirmed to be HIV negative (due to the unknown 
effect of immunodeficiency on cough). The exclusion criterion 
was no adequate recording during the study period.
Clinicians treated patients for tuberculosis according to the 
Peruvian national guidelines, using direct observation of every 
treatment dose. Patient treatment was not modified by this 
study. They were followed in our study until 62 days after treat-
ment initiation. Cough was recorded among all suspected tuber-
culosis cases at the time of participant enrollment. Participants 
were asked to complete a previously published questionnaire 
regarding their socioeconomic status [9].
This study was approved by the ethics committees of both 
participating hospitals, A.B. PRISMA and Universidad Peruana 
Cayetano Heredia (UPCH) in Lima, Peru; and Johns Hopkins 
University in Baltimore, Maryland.
Cough Frequency Assessment
The Cayetano Cough Monitor (CayeCoM) device is a semiauto-
mated ambulatory cough monitor that [9], along with our pre-
viously developed algorithm, identifies cough with a sensitivity 
of 75.5% and a Birring specificity [10] of 99.3% among adults 
with pulmonary tuberculosis [7]. All recordings that malfunc-
tioned or were of poor sound quality due to high background 
noise were excluded. Recordings with a positive cough sound 
were further validated by 2 trained nurses who were responsible 
for listening to the portions of the recording identified by the 
algorithm to confirm each event as a “cough.” To reduce bias, 
recordings were randomly and blindly assigned to each nurse. 
For quality control purposes, a random subset of recordings was 
listened to by both nurses, and their agreement was assessed by 
calculating the κ statistic.
Microbiological Assessment
Standard instructions were given to participants to collect ear-
ly-morning sputum samples by deep coughing. We obtained 
a single morning sputum sample on the day that each partic-
ipant started treatment (day 0), and on days 3, 7, 14, 21, 30, 
and 60 of treatment. All sputum samples underwent microbi-
ological protocols at UPCH for auramine-stained smears, and 
the microscopic-observation drug susceptibility (MODS) broth 
culture assay incorporating drug susceptibility testing for iso-
niazid and rifampicin, as previously described [9, 11–13]. The 
numbers of acid-fast bacilli visualized by auramine microscopy 
were recorded as the smear grade. In MODS culture–positive 
samples, the number of days from inoculation to positive was 
recorded to assess viable bacillary load in sputum, and defined 
as time to positivity (TTP). TTP predicts treatment response 
and correlates with the number of colony-forming units (CFU) 
prior to and during treatment [14–16].
Statistical Analysis
All analyses were conducted using Stata statistical software 
version 14 (StataCorp LP, College Station, Texas), under a 95% 
confidence level.
Cough Definitions
Cough was more likely to occur in clusters, termed salvos, 
rather than individually. Therefore, cough episodes were ana-
lyzed rather than individual cough events. A cough episode was 
defined as all consecutive cough events that occurred without 
a cough-free pause of 2 seconds or more [7]. Cough frequency 
was defined as the number of cough episodes/hour.
Based on previous findings by other groups [17, 18], which 
used cough events rather than episodes, we defined “no cough” 
as ≤0.7 cough events/hour, and cough cessation was defined as 
the first of 2 consecutive recordings with no cough.
Mycobacterial Load Calculations
To estimate CFUs from TTP, we used the equation [log10 CFU 
= 5.1 − (0.16×TTP)], based on our group’s data on quantitative 
cultures [15, 19]. Therefore, CFUs were estimated only for pos-
itive cultures, and all negative and indeterminate cultures were 
excluded from CFU analyses. Smear conversion was defined as 
the first negative smear with no subsequent positive smear; cul-
ture conversion was defined as the first negative culture with no 
subsequent positive culture.
Circadian cycle of cough frequency. Cough frequency was 
modeled using nested negative binomial regression with ran-
dom effects with an exchangeable correlation structure at the 
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level of participant and treatment day, and a robust variance 
estimate. This was chosen based on a comparison of quasi-likeli-
hood under the independence model criterion statistics between 
models with alternative correlation structures. To describe cir-
cadian cycles of cough, this model was adjusted for the hour 
of the day using harmonic sine and cosine terms as shown in 
Supplementary Equation 1. To test whether the circadian cycle 
varied with duration of treatment, models were fitted (1) sepa-
rately by treatment day and (2) adjusting for treatment day, with 
interactions between treatment day and sine/cosine terms.
Risk factors associated with increased cough fre-
quency. Random-effects negative binomial regression with 
a participant-level random intercept was used to evaluate the 
association between cough frequency and mycobacterial load, 
as well as prior participant-reported tuberculosis, and socioeco-
nomic status (monthly income). A final multivariable model was 
created, adjusting for risk factors found to be significant (P ≤ .05) 
in univariable analysis. In addition, because the relationship 
between the duration of treatment and cough frequency was 
nonlinear, both day of treatment and day of treatment squared 
were included as independent variables. TTP provides a more 
precise quantification of bacillary load, so it was preferred over 
smear- or culture-positive status in the multivariable analysis.
Impact of appropriate treatment. The effects of the duration 
of appropriate treatment on cough frequency, smear grade, 
and MODS culture conversion were analyzed using Cox pro-
portional hazard models. In this model, cough frequency was 
assessed as (1) a 2-fold reduction compared to the pretreatment 
cough frequency, as previously used by Loudon and Spohn [5], 
and (2) as no cough.
Feasibility of Shorter Recordings
Cough frequency calculated over a full day (≥23.5 hours) was 
compared to cough frequencies calculated over shorter periods 
(2- to 12-hour periods during the day). Cough recordings were 
split randomly into a discovery set (70% of recordings) and a vali-
dation set (30% of recordings). Using the discovery dataset, cough 
frequency was calculated during 2- to 12-hour periods through-
out the day, and Spearman (nonparametric) correlation between 
total cough episodes occurring over each shortened window and 
total cough episodes over the full ≥23.5 hours was calculated. The 
time of day that correlated most highly with 24-hour cough was 
identified. This result, and the individual intraclass  correlation 
coefficient, was then tested in the validation dataset.
RESULTS
Demographics and Pretreatment Assessment of Microbiology
Ninety-seven adults were enrolled in the parent study, who con-
tributed with 957 recordings, with 685 of 1642 (42%) record-
ings excluded for technical reasons (Supplementary Table 1). 
Of these, 66 met inclusion criteria for the current study, and 
2 were excluded because they had no adequate cough record-
ing, so the study group consisted of 64 participants (Figure 1). 
Of these participants, all had at least 1 positive MODS culture, 
which included their first sputum sample for 95% of partici-
pants. Baseline demographic data are shown in Table 1.
Cough Validation and Characteristics
The median length of cough episodes was 0.61 seconds (inter-
quartile range [IQR], 0.26–2.2), and 90% were <3.9 seconds 
long. Fifty percent of episodes contained only a single cough 
event, 24% had 2 cough events, and the remaining 26% con-
tained ≥3 events. The maximum number of total cough events 
in a single episode was 21.
There was good agreement among the 43% subset of record-
ings reviewed by both nurses, with a Cohen κ statistic of 0.93.
Circadian Cycle of Cough Frequency
Based on model estimates, the highest pretreatment cough fre-
quency occurred from 1 pm to 2 pm and the lowest from 1 am to 
2 am (2.4 vs 1.1 cough episodes/hour, respectively). Thus, cough 
episodes were twice as frequent during daytime as nighttime. 
This circadian cycle was present throughout the study period 
(Figure 2). For example, after 14 days of treatment, cough epi-
sodes per hour were 1.5 from 1 to 2 pm vs 0.73 from 1 to 2 am.
Risk Factors Associated With Increased Cough Frequency
Cough frequency was independently associated with day of 
treatment (rate ratio [RR] per 10  days, 0.37; P  <  .01), day of 
treatment squared (RR, 1.3; P  <  .001), and TTP (RR, 0.93; P 
< .01) in the multivariable model (Table 2). Pretreatment cough 
frequency was correlated with cough frequency on treatment 
Figure 1. Flowchart for the Cayetano Cough Monitor Study. Abbreviations: HIV, 
human immunodeficiency virus; TB, tuberculosis.
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day 3 (Spearman ρ, 0.47; 95% confidence interval [CI], .095–
.73; P  =  .02); but was not statistically significantly correlated 
with cough frequency at later time points. Cough frequency 
decreased with increasing duration of treatment (Supplementary 
Figure 1). Cough frequency was not independently significantly 
associated with income or prior tuberculosis (Table 2).
Impact of Appropriate Treatment
Pretreatment median cough episodes per hour was 2.3 (IQR, 
1.2–4.1), which after 14  days of treatment decreased to 0.48 
(IQR, 0.0–1.4; P < .001) and by the end of the study decreased to 
0.18 (IQR, 0.0–0.59; P < .001 compared with pretreatment). By 
2 weeks of continuous treatment, the probability of cough cessa-
tion, smear conversion, and MODS culture conversion was 42% 
(95% CI, 25%–64%), 26% (95% CI, 17%–39%), and 29% (95% 
CI, 19%–41%) respectively; by the end of the study the probabil-
ities increased to 51% (95% CI, 33%–72%), 85% (95% CI, 73%–
93%), and 94% (95% CI, 85%–98%), respectively (Figure 3).
The median time to halving of cough frequency was 7.0 days, 
and cough frequency had at least halved for 73% of participants by 
day 14. Participants with no cough pretreatment continued to have 
no cough throughout treatment. A  higher pretreatment cough 
frequency was associated with a faster halving of cough frequency 
during treatment (hazard ratio, 1.2; P = .02). Other pretreatment 
factors (eg, age, sex) were not significantly associated with time to 
halving of cough frequency or time to achieve no cough. When 
cough trends were examined on a participant-by-participant 
basis, most showed a strong and immediate decrease in cough fre-
quency after treatment, following the overall trend.
There was no statistically significant association between 
pretreatment cough frequency (median, 2.3 cough episodes/
hour; IQR, 1.2–4.1) and time to smear conversion (median, 21 
Figure 2. Circadian cycle of cough frequency during treatment for study group. A, Smoothed trends in cough from day –1 to day 7 of treatment. Each day begins at 9 am, 
as this is the time when recordings began. B, Separate negative binomial generalized estimating equation models fitted for each day following treatment. All recordings, 
regardless of total length, were included (n = 12 108 hours of recording). Random-effects modeling was used to adjust for study participant. Circadian cycles of cough were 
reflected by sine/cosine terms.
Table 1. Baseline Demographic Characteristics of Study Participants
Variable Study Group
Total participants 64
Male participants (%, 95% CI) 44 (69%, 57%–80%)
Median age, y, at study enrollment (IQR) 32 (22–44)
Pretreatment culture positive (%, 95% CI) 61 (95%, 90%–100%)
Pretreatment culture negative (%, 95% CI) 1.0 (1.6%, 0.0–4.7%)
Pretreatment indeterminate culture  
(%, 95 CI)
2.0 (3.1%, 0.0–7.5%)
Median pretreatment TTP, d (IQR) 7.0 (6.0–9.0)
Pretreatment negative smear (%, 95% CI) 19 (30%, 18%–41%)
Pretreatment paucibacillary smear  
(%, 95% CI)
5.0 (7.8%, 1.1%–15%)
Pretreatment smear + (%, 95% CI) 19 (30%, 18%–41%)
Pretreatment smear ++ (%, 95% CI) 8.0 (13%, 4.2%–21%)
Pretreatment smear +++ (%, 95% CI) 13 (20%, 10%–30%)
Drug-susceptible participants (%, 95% CI) 64 (100%, 100%–100%)
Total hours of recording 12 108
Total participant-days of recordingsa 661 (670 unique recordings)
Total complete daily recordingsb 267 (267 unique recordings)
Patient characteristics and microbiological data corresponding to study group.
Abbreviations: +, 20–199 acid-fast bacilli per 40 fields at 400× magnification; ++, 5–50 
acid-fast bacilli per field at 400× magnification; +++, >50 acid-fast bacilli per field at 400× 
magnification; CI, confidence interval; IQR, interquartile range; TTP, time to positivity of 
microscopic-observation drug susceptibility culture.
aTotal participant-days of recordings is the number of days within the study that contrib-
uted with recordings; if a participant had multiple unique recordings on the same day, it 
will still contribute to only 1 participant-day of recording.
bTotal complete daily recordings were recordings that were at least 23.5 hours long.
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days of treatment; IQR, 6–32) or culture conversion (median, 
29 days; IQR, 13–61). Throughout the study, the cough fre-
quency on days when participants had positive MODS cul-
tures was approximately double the cough frequency on days 
when cultures were negative (univariate analysis RR, 2.3; P 
< .001). When assessing bacillary load, TTP was inversely 
associated with cough frequency such that as TTP increased 
indicating reduced bacillary load, cough frequency decreased 
(RR, 0.93; P < .01) (Table 2). The relationship between cough 
frequency, TTP, and estimated log10 CFU over time is shown 
in Supplementary Figure 2. There was a significant association 
(P < .001) between TTP and sputum smear positivity in pre-
treatment samples (Supplementary Figure 3).
Among the 41% (26/64) of participants with matched cough 
recordings and sputum samples available pretreatment, median 
cough frequency was 2.3 cough episodes per hour (IQR, 1.2–
4.1); median TTP was 6.0 days (IQR, 6.0–7.0), and 12% initially 
had no cough (Supplementary Table  2). At 2 weeks of treat-
ment, 77% (49/64) of participants had matched recordings and 
sputum samples, with a median cough frequency of 0.43 (IQR, 
0.0–1.1) and a median TTP of 11 (IQR, 10–13). At day 60, 65% 
(15/23) of participants with matched samples had no cough.
Comparing participants who were lost to follow-up on or 
before day 14 to those who continued past this point, there were 
no statistically significant differences in baseline cough (2.2 vs 
2.4 cough episodes/hour; P = 1) initial smear results (++: 14% 
vs 12%; P = .16); or baseline TTP (6.5 vs 7.0; P = .11). Those who 
were lost to follow-up were also similar in sex, were of similar 
age, and were no more likely to have had prior tuberculosis.
Feasibility of Shorter Recordings
Among 4-hour recordings, afternoon recordings (2–6 pm) had 
the highest correlation with 24-hour recordings (ρ = 0.86; stand-
ard error = 0.04). The least representative 4-hour period occurred 
in the evening (10 pm–2 am). Daytime shorter recordings corre-
lated best with 24-hour recordings (Supplementary Table 3).
DISCUSSION
Tuberculosis transmission occurs by aerosol spread, and the 
bacterial burden within sputum is often used as a proxy for 
infectiousness [20]. However, airborne tuberculosis transmis-
sion can only occur if there is a mechanism for distribution, such 
as expulsion through cough. Cough frequency in tuberculosis 
has been poorly studied with only a single study reported nearly 
50 years ago. This study only observed patients at night and did 
not evaluate subject-specific dynamics over time [5]. To ensure 
adequate prevention strategies, an improved understanding of 
cough dynamics, before and during treatment, is required.
Our group used a previously validated cough monitor and 
algorithm to record cough episodes from 64 HIV-negative par-
ticipants diagnosed with drug-susceptible pulmonary tubercu-
losis. We observed that cough frequency varied throughout the 
Table 2. Risk Factors for Cough Frequency in Univariable and Multivariable Negative Binomial Model Adjusting for Study Participant
Risk Factor 
Univariable Analysis
(64 Participants,  
661 Observations)
Multivariable Analysis
(59 Participants,  
173 Observations)
RR P Value 95% CI RR P Value 95% CI
Treatment day (per 10 d) 0.68 <.001 .62–.75 0.37 .001 .20–.68
Treatment day squared 0.97 <.001 .95–.98 1.28 <.001 1.11–1.46
Monthly income (Peruvian soles) 1.00 .942 1.00–1.00
Prior tuberculosis, yes/no 1.02 .719 .93–1.11
MODS culture positive 2.34 <.001 1.70–3.24
Time to positivity, d 0.90 <.001 .87–.94 0.93 .005 .89–.98
Time to positivity (categorical)
 5–7 d Reference
 8–10 d 0.75 .115 .52–1.07
 ≥11 d 0.47 <.001 .33–.68
Smear (categorical)
 Negative Reference
 Paucibacillary 1.62 .052 1.00–2.64
 + 2.65 <.001 1.89–3.71
 ++ 3.78 <.001 2.58–5.54
 +++ 3.89 <.001 2.55–5.94
Sex, female 1.33 .032 1.02–1.74 1.23 .292 .83–1.83
Age, y (per 10 y) 1.41 <.001 1.29–1.54 1.11 .100 .98–1.25
Results of the univariable and multivariable negative binomial models examining cough frequency. A random-effects negative binomial model was used to adjust for study participant.
Abbreviations: +, 20–199 acid-fast bacilli per 40 fields at 400× magnification; ++, 5–50 acid-fast bacilli per field at 400× magnification; +++, >50 acid-fast bacilli per field at 400× magnifica-
tion; CI, confidence interval; MODS, microscopic-observation drug susceptibility assay; RR, rate ratio.
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day, with the highest frequency in the afternoon, a time of day 
when patients are likely to be active outside their homes, and 
lowest at nighttime, likely during sleep [21]. When comparing 
our results to those of Loudon and Spohn [5], we found a simi-
lar pattern of decrease in nighttime 8-hour cough frequency (11 
pm–7 am) over our study period. We also found that shorter peri-
ods of cough recording have reasonable agreement with 24-hour 
recordings [22]. Our study also shows that cough, at a lower fre-
quency, can continue within 2 months of treatment, supporting 
previous results [4, 23]. However, it should be noted that cough 
alone can be a nonspecific symptom for tuberculosis; thus, both 
cough frequency and sputum MODS cultures were assessed.
Increased cough frequency was associated with MODS cul-
ture positivity, as well as decreased time to positivity, a surrogate 
for bacterial load [15, 16]. This suggests that cessation of cough 
is associated with sputum bacillary load and MODS culture con-
version to negative during the first 2 months of treatment, which 
suggests that cough reflects treatment response [4]. Current 
guidelines note that following 2 weeks of tuberculosis treatment, 
infectiousness is greatly reduced [24–26], despite the presence 
of viable pathogens far beyond this time [27]. This implies that 
infectivity not only depends on microbiology positivity, but also 
on other factors such as cough frequency [28]. In support of this, 
we found that cough frequency dropped rapidly in the first days 
of treatment. Estimated CFU counts dropped faster within the 
first days of treatment [29–31], alongside an exponential decline 
in cough frequency. This supports the observation that within 
the first days of treatment a large proportion of the actively 
growing mycobacteria are killed [29], and that effective treat-
ment may rapidly diminish transmission [32].
Of the 26 participants who provided concurrent cough record-
ings and sputum samples prior to commencing treatment, almost 
one-eighth had no cough. “No cough” patients with pulmonary 
tuberculosis have been described previously [33, 34]; however, 
this is the first time this has been quantified. The World Health 
Organization, the International Union Against Tuberculosis 
and Lung Disease, and the Royal Netherlands Tuberculosis 
Association define case detection when cough lasts between 2 
and 3 weeks, the entry point for routine tuberculosis diagnostic 
screening [35]. Thus, restriction of tuberculosis diagnostic test-
ing to those defined within the current “case detection” defini-
tion worldwide may miss a substantial number of patients with 
active pulmonary disease, and therefore screening must also 
consider that cough might not be present. By not relying solely 
on 2–3 weeks of cough as the entry point for screening, this will 
increase the number of diagnosed and treated patients, which 
will increase the positive impact of the tuberculosis program, 
albeit at the cost of more people being eligible for screening.
A strength of this study is that it used an objective cough moni-
tor that has been validated in adults with tuberculosis [6, 7], with 
a sensitivity of 75.5%, comparable to that of other semiautomated 
methods [36, 37], and utilized day-long recordings that enabled 
determination of cough frequency by hour. A limitation of our 
method is the large proportion of recordings that could not be 
processed due to relatively high levels of background noise, and 
the relatively smaller number of early-morning (6–9 am) record-
ings available. We are working to solve this technical issue by the 
development of a second-generation accelerometer-based cough 
monitor [38]. In addition, we did not quantify CFUs but instead 
mathematically estimated CFUs from other quantitative data in 
MODS cultures [15, 19]. Our formula provides similar results to 
those obtained by another group who modeled CFUs from TTP 
in Mycobacteria Growth Indicator Tube (MGIT) culture [16]. 
Another limitation is that participants enrolled in this study 
were recruited from 2 tertiary academic hospitals, and might not 
reflect the broader population of tuberculosis in the community.
The current convention for infection control is that, following 
2 weeks of adequate treatment, patients with tuberculosis pose 
a significantly reduced risk of onward transmission, so it is safe 
to consider discontinuing infection control practices including 
respiratory isolation [24–26, 39]. Despite the fact that bacterial 
growth can occur from sputum obtained as late as 60 days into 
adequate treatment [27], our data show a rapid drop in cough fre-
quency, which is associated with microbiological conversion. This 
supports earlier findings which show that pulmonary tuberculo-
sis transmission is greatly reduced once adequate treatment starts 
Figure 3. Kaplan-Meier curves for time to coughing cessation and microbiologi-
cal conversion in study group. Cough cessation represents the time to the first of 
2 consecutive recordings with a cough frequency of ≤0.7 cough events per hour 
(considered “no cough”); by day 14, the probability of cough cessation was 42% 
(95% confidence interval [CI], 25%–64%), and by day 60 the probability was 51% 
(95% CI, 33%–72%). Smear conversion represents the time to the first negative 
smear with no subsequent positive smear; by day 14, the probability of smear con-
version was 26% (95% CI,  17%–39%), and by day 60 the probability was 85% 
(95% CI, 73%–93%). Microscopic-observation drug susceptibility (MODS) culture 
conversion represents time to the first negative culture with no subsequent posi-
tive culture; by day 14, the probability of MODS culture conversion was 29% (95% 
CI, 19%–41%), and by day 60 the probability was 94% (95% CI, 85%–98%).
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[32, 39, 40], and suggests that tuberculosis treatment response 
could be indirectly measured by assessing cough frequency.
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